AscenD-LB Study - clinical study evaluating improvement in cognitive function in DLB patients | Lewy Body Dementia Association LBDA

AscenD-LB Study - clinical study evaluating improvement in cognitive function in DLB patients

What is this study about? 

The purpose of this study (AscenD-LB) is to understand if neflamapimod has an effect on cognitive function (attention, memory) in those with dementia with Lewy bodies (DLB).

What is involved? 

Participants of this study will be randomly assigned to either an oral dose of neflamapimod or an inactive substitute (placebo) for 16 weeks. Neither the study participant nor the researcher will know who is receiving neflamapimod, which is called a double-blind study. Study participants may require MRI, CT, DaTscan, cognitive tests, electrocardiodiagram, physical examination, and biomarker testing. information available in the link here.

What is Neflamapimod

Neflamapimod is an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, which leads to neurodegeneration.

Who can participate? 

An individual may be able to join the study if he/she meets the following criteria:

  • Man or woman 55 years of age or older
  • Individual or individual's legally authorized representative willing and able to provide informed consent
  • Person with probable DLB
  • Currently receiving cholinesterase inhibitor therapy
  • Normal or corrected eyesight and auditory ability
  • No history of learning difficulties
  • Have reliable informant or caregiver

Study Locations:

The AscenD-LB study will be conducted at the following locations:

Site Location Site Contact Email
University of Kansas Medical Center Kansas City, KS Emily Gamel
University of Rochester Rochester, NY Nicole Guerrero
University of Washington Seattle, WA Yeung Tutterrow
Cleveland Clinic - Las Vegas Las Vegas, NV Marlen Ibarra
Northwest Clinical Research Center Bellevue, WA Leslie Gills
Ohio State University Columbus, OH Brooke Eiginger
Summit Research Network Portland, OR Amanda Feldman
Massachusetts General Hospital Charlestown, MA Brooke Fortin
Oregon Health and Science University (OHSU) Portland, OR Audrey Anderson
John Wayne Cancer Institute
(Pacific Neuroscience Institute)
Santa Monica, CA Mini Gill
National Clinical Research, Inc.
Alzheimer's Research Center
Richmond, VA Kelly Gilpatrick
New York Presbyterian Hospital - Columbia University Medical Center New York, NY Ruth Tejeda
Y&L Advance Health Care dba Elite Clinical Research Miami, FL Nuvia Herrera
University of Virginia Charlottesville, VA Colleen Webber
University of Michigan Ann Arbor, MI Jackie Dobson
Jefferson University Hospitals Philadelphia, PA Aaron Roberts
Mayo Clinic Rochester, MN Kevin Nelson
University of North Carolina Chapel Hill, NC Carlos Velez
Cleveland Clinic Cleveland, OH Christine Whitman
University of California San Diego, CA Rachel Schade
University of Colorado Aurora, CO Abigail Simpson
Inland Northwest Research Spokane, WA Deann Dickinson

Click Here

Study Sponsor: 

EIP Pharma